Literature DB >> 12163106

Drotaverine interacts with the L-type Ca(2+) channel in pregnant rat uterine membranes.

Zsuzsanna Tömösközi1, Olivier Finance, Péter Arányi.   

Abstract

The effect of the isoquinoline derivative, drotaverine on the specific binding of [(3)H]nitrendipine and [(3)H]diltiazem to pregnant rat uterine membranes was examined. Drotaverine inhibited the specific [(3)H]nitrendipine and [(3)H]diltiazem bindings with IC(50) values of 5.6 and 2.6 microM, respectively. Saturation studies showed that diltiazem caused a significant increase in the maximum binding density without changing the K(D) of [(3)H]nitrendipine while drotaverine increased both the K(D) and the B(max) of [3H]nitrendipine. The dissociation kinetics of both [3H]nitrendipine and [(3)H]diltiazem were accelerated by drotaverine. These results suggest that drotaverine has a negative allosteric interaction with the binding sites for 1,4-dihydropyridines and 1,5-benzothiazepines on the L-type Ca(2+) channel in pregnant rat uterine membranes, which may have implications as to the potential usefulness of this drug in aiding child delivery.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12163106     DOI: 10.1016/s0014-2999(02)01993-3

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  2 in total

1.  Development and Validation of a Stability-Indicating RP-HPLC Method for the Estimation of Drotaverine Impurities in API and Pharmaceutical Formulation.

Authors:  Veera Raghava Raju Thummala; Satya Sankarsana Jagan Mohan Tharlapu; Vijay Kumar Rekulapalli; Mrutyunjaya Rao Ivaturi; Someswara Rao Nittala
Journal:  Sci Pharm       Date:  2013-10-21

Review 2.  Integrated Computational Approaches and Tools forAllosteric Drug Discovery.

Authors:  Olivier Sheik Amamuddy; Wayde Veldman; Colleen Manyumwa; Afrah Khairallah; Steve Agajanian; Odeyemi Oluyemi; Gennady Verkhivker; Ozlem Tastan Bishop
Journal:  Int J Mol Sci       Date:  2020-01-28       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.